Advertisement

Establishment of a system to evaluate the therapeutic effect and the dynamics of an investigational drug on ulcerative colitis using human colonic organoids

  • Ryu Nishimura
  • Tomoaki Shirasaki
  • Kiichiro TsuchiyaEmail author
  • Yoshihide Miyake
  • Yusuke Watanabe
  • Shuji Hibiya
  • Sho Watanabe
  • Tetsuya Nakamura
  • Mamoru Watanabe
Original Article—Alimentary Tract

Abstract

Background

Ulcerative colitis (UC) is a chronic inflammatory disease of the colon with an intractable, recurrent course. The goal of UC therapy is to target mucosal healing because immune-suppressive therapy for UC frequently results in relapse. However, few drugs directly target mucosal healing. We, therefore, aim to evaluate the therapeutic effect of an investigational drug on intestinal epithelial cells in an in vitro UC model using human colonic organoids.

Methods

Colonic organoids were isolated from human colon and cultured. A mixture of cytokines and bacterial components were used to mimic UC in humans. The effect of the investigational drug on colonic organoid was evaluated by microarray analysis and 3D immunofluorescence. The enrichment of stem cells was assessed with a colony formation assay.

Results

Inflammatory stimulation resulted in a significant induction of inflammatory-related genes in colonic organoids whereas cell differentiation was suppressed. Treatment with the investigational drug KAG-308 showed reciprocal dynamics of gene expression to inflammatory stimulation, which resulted in not only the suppression of immune response but also the promotion of cellular differentiation towards secretory lineages. Moreover, SPDEF and Reg4 were identified as novel targets for the enrichment of intestinal epithelial stem cells and mucosal healing.

Conclusions

The establishment of in vitro UC model using human colonic organoid could reveal the effects and targets of investigational drugs in intestinal epithelial cells under inflammation conditions. Further maturation of this system might be more efficient to predict the effect on UC, as compared with the use of animal model, for the development of new drugs.

Keywords

Inflammatory bowel disease In vitro human model Evaluation system Investigational drug 

Abbreviations

IBD

Inflammatory bowel disease

UC

Ulcerative colitis

DSS

Dextran sulphate sodium

AOM

Azoxymethane

IECs

Intestinal epithelial cells

NF-κB

Nuclear factor-κB

PGE2

Prostaglandin E2

EP4

Prostaglandin E2 receptor 4

GSEA

Gene set enrichment analysis

TLRs

Toll-like receptors

IL

Interleukin

ROS

Reactive oxygen species

LPS

Lipopolysaccharide

TNF

Tumour necrosis factor

CLDN18

Claudin-18

CIITA

Class II major histocompatibility complex transactivator

DAPI

4′,6-diamidino-2-phenylindole

Reg4

Regenerating family member 4

SPDEF

SAM-pointed domain containing ETS transcription factor

Duoxa2

Dual oxidase maturation factor 2

ALDH1

Aldehyde dehydrogenase 1

Lgr5

Leucine-rich repeat-containing G-protein coupled receptor 5

Hes1

Hairy and enhancer of split 1

Atoh1

Atonal bHLH transcription factor 1

TFF3

Trefoil factor 3

MUC2

Mucin 2

CgA

Chromogranin A

Notes

Acknowledgements

This work was supported by scientific Research, from the Japanese Ministry of Education, Culture, Sports, Science and Technology as follows (KAKENHI grant numbers 24590935, 25114703, 25130704, 26221307, 15H04808, 16H06770, 17H06654, 17K15930, 17K19513); Japan Foundation for Applied Enzymology; the Health and Labor Sciences Research Grant from the Japanese Ministry of Health, Labor and Welfare (MHLW) as follows (Grant number 14526073); The Practical Research for Innovative Cancer Control, Rare/Intractable Diseases from Japan Agency for Medical Research and Development (AMED) as follows (Grant numbers 15Ack0106017h0002, 16ck0106017h0003, 16ek0109456h0003); Research Grant of the Princess Takamatsu Cancer Research Fund; Naoki Tsuchida Research Grant.

Compliance with ethical standards

Conflict of interest

YM and YW are employed by Kaken Pharmaceutical Co., Ltd. KT has received research funding (collaborative research) provided by Kaken Pharmaceutical Co., Ltd.

Author contributions

MW, TN and KT designed the experiments and acquired data. TS and SH established inflammatory stimulation of the organoids. RN and SW assessed the effect of KAG-308 on the organoids. YM and YW assessed the effect of KAG-308 on DSS colitis model in mice. KT and MW coordinated the projects and drafted the manuscript.

Supplementary material

535_2018_1540_MOESM1_ESM.pdf (1.5 mb)
Supplementary material 1 (PDF 1502 kb)
535_2018_1540_MOESM2_ESM.pdf (9.1 mb)
Supplementary material 2 (PDF 9352 kb)
535_2018_1540_MOESM3_ESM.pdf (2.9 mb)
Supplementary material 3 (PDF 2932 kb)
535_2018_1540_MOESM4_ESM.pdf (3.5 mb)
Supplementary material 4 (PDF 3541 kb)
535_2018_1540_MOESM5_ESM.pdf (3.4 mb)
Supplementary material 5 (PDF 3529 kb)
535_2018_1540_MOESM6_ESM.pdf (9.9 mb)
Supplementary material 6 (PDF 10088 kb)
535_2018_1540_MOESM7_ESM.pdf (404 kb)
Supplementary material 7 (PDF 404 kb)
535_2018_1540_MOESM8_ESM.pdf (417 kb)
Supplementary material 8 (PDF 417 kb)
535_2018_1540_MOESM9_ESM.doc (77 kb)
Supplementary material 9 (DOC 77 kb)
535_2018_1540_MOESM10_ESM.docx (18 kb)
Supplementary material 10 (DOCX 17 kb)
535_2018_1540_MOESM11_ESM.docx (23 kb)
Supplementary material 11 (DOCX 23 kb)
535_2018_1540_MOESM12_ESM.docx (19 kb)
Supplementary material 12 (DOCX 19 kb)
535_2018_1540_MOESM13_ESM.docx (19 kb)
Supplementary material 13 (DOCX 19 kb)

References

  1. 1.
    Arora Z, Shen B. Biological therapy for ulcerative colitis. Gastroenterol Rep. 2015;3:103–9.CrossRefGoogle Scholar
  2. 2.
    Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380:1606–19.CrossRefGoogle Scholar
  3. 3.
    Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 2014;7:6–19.CrossRefGoogle Scholar
  4. 4.
    Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11:769–84.CrossRefGoogle Scholar
  5. 5.
    Okamoto R, Watanabe M. Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J Gastroenterol. 2016;51:11–21.CrossRefGoogle Scholar
  6. 6.
    Valatas V, Vakas M, Kolios G. The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol. 2013;305:G763–85.CrossRefGoogle Scholar
  7. 7.
    Yui S, Nakamura T, Sato T, et al. Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5+ stem cell. Nat Med. 2012;18:618–23.CrossRefGoogle Scholar
  8. 8.
    Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262–5.CrossRefGoogle Scholar
  9. 9.
    Hibiya S, Tsuchiya K, Hayashi R, et al. Long-term inflammation transforms intestinal epithelial cells of colonic organoids. J Crohns Colitis. 2017;11:621–30.Google Scholar
  10. 10.
    MacFie TS, Poulsom R, Parker A, et al. DUOX2 and DUOXA2 form the predominant enzyme system capable of producing the reactive oxygen species H2O2 in active ulcerative colitis and are modulated by 5-aminosalicylic acid. Inflamm Bowel Dis. 2014;20:514–24.CrossRefGoogle Scholar
  11. 11.
    Miyoshi H, VanDussen KL, Malvin NP, et al. Prostaglandin E2 promotes intestinal repair through an adaptive cellular response of the epithelium. EMBO J. 2017;36:5–24.CrossRefGoogle Scholar
  12. 12.
    Kawahara K, Hohjoh H, Inazumi T, et al. Prostaglandin E2-induced inflammation: relevance of prostaglandin E receptors. Biochim Biophys Acta. 2015;1851:414–21.CrossRefGoogle Scholar
  13. 13.
    O’Callaghan G, Houston A. Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? Br J Pharmacol. 2015;172:5239–50.CrossRefGoogle Scholar
  14. 14.
    Watanabe Y, Murata T, Amakawa M, et al. KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration. Eur J Pharmacol. 2015;754:179–89.CrossRefGoogle Scholar
  15. 15.
    Fujii S, Suzuki K, Kawamoto A, et al. PGE2 is a direct and robust mediator of anion/fluid secretion by human intestinal epithelial cells. Sci Rep. 2016;6:36795.CrossRefGoogle Scholar
  16. 16.
    Planell N, Lozano JJ, Mora-Buch R, et al. Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. Gut. 2013;62:967–76.CrossRefGoogle Scholar
  17. 17.
    Wong WM, Poulsom R, Wright NA. Trefoil peptides. Gut. 1999;44:890–5.CrossRefGoogle Scholar
  18. 18.
    Zwiers A, Fuss IJ, Leijen S, et al. Increased expression of the tight junction molecule claudin-18 A1 in both experimental colitis and ulcerative colitis. Inflamm Bowel Dis. 2008;14:1652–9.CrossRefGoogle Scholar
  19. 19.
    Dotti I, Mora-Buch R, Ferrer-Picon E, et al. Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis. Gut. 2017;66:2069–79.CrossRefGoogle Scholar
  20. 20.
    Kazanjian A, Noah T, Brown D, et al. Atonal homolog 1 is required for growth and differentiation effects of notch/gamma-secretase inhibitors on normal and cancerous intestinal epithelial cells. Gastroenterology. 2010;139(918–928):928.e911–6.Google Scholar
  21. 21.
    Zheng X, Tsuchiya K, Okamoto R, et al. Suppression of hath1 gene expression directly regulated by hes1 via notch signaling is associated with goblet cell depletion in ulcerative colitis. Inflamm Bowel Dis. 2011;17:2251–60.CrossRefGoogle Scholar
  22. 22.
    Lo YH, Chung E, Li Z, et al. Transcriptional regulation by ATOH1 and its target SPDEF in the intestine. Cell Mol Gastroenterol Hepatol. 2017;3:51–71.CrossRefGoogle Scholar
  23. 23.
    Sasaki N, Sachs N, Wiebrands K, et al. Reg4+ deep crypt secretory cells function as epithelial niche for Lgr5+ stem cells in colon. Proc Natl Acad Sci USA. 2016;113:E5399–407.CrossRefGoogle Scholar
  24. 24.
    Nanakin A, Fukui H, Fujii S, et al. Expression of the REG IV gene in ulcerative colitis. Lab Investig. 2007;87:304–14.CrossRefGoogle Scholar
  25. 25.
    Jiang GL, Nieves A, Im WB, et al. The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. J Pharmacol Exp Ther. 2007;320:22–8.CrossRefGoogle Scholar
  26. 26.
    Ruijtenberg S, van den Heuvel S. Coordinating cell proliferation and differentiation: antagonism between cell cycle regulators and cell type-specific gene expression. Cell Cycle. 2016;15:196–212.CrossRefGoogle Scholar
  27. 27.
    Xia K, Xue H, Dong D, et al. Identification of the proliferation/differentiation switch in the cellular network of multicellular organisms. PLoS Comput Biol. 2006;2:e145.CrossRefGoogle Scholar
  28. 28.
    Tsuchiya K, Nakamura T, Okamoto R, et al. Reciprocal targeting of Hath1 and beta-catenin by wnt glycogen synthase kinase 3 beta in human colon cancer. Gastroenterology. 2007;132:208–20.CrossRefGoogle Scholar
  29. 29.
    Okamoto R, Tsuchiya K, Nemoto Y, et al. Requirement of Notch activation during regeneration of the intestinal epithelia. Am J Physiol Gastrointest Liver Physiol. 2009;296:G23–35.CrossRefGoogle Scholar
  30. 30.
    Izumi H, Minegishi M, Sato Y, et al. Bifidobacterium breve alters immune function and ameliorates DSS-induced inflammation in weanling rats. Pediatr Res. 2015;78:407–16.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2019

Authors and Affiliations

  • Ryu Nishimura
    • 1
  • Tomoaki Shirasaki
    • 1
  • Kiichiro Tsuchiya
    • 1
    Email author return OK on get
  • Yoshihide Miyake
    • 2
  • Yusuke Watanabe
    • 2
  • Shuji Hibiya
    • 1
  • Sho Watanabe
    • 1
  • Tetsuya Nakamura
    • 1
    • 3
  • Mamoru Watanabe
    • 1
  1. 1.Department of Gastroenterology and HepatologyGraduate School, Tokyo Medical and Dental UniversityTokyoJapan
  2. 2.Pharmacology Department, Drug Research CenterKaken Pharmaceutical Co., LtdKyotoJapan
  3. 3.Department of Advanced Therapeutics for Gastrointestinal DiseasesGraduate School, Tokyo Medical and Dental UniversityTokyoJapan

Personalised recommendations